IntrOduCtIOn
Myositis is a diverse group of autoimmune diseases that includes polymyositis (PM), dermatomyositis (DM) and inclusion body myositis (IBM). 1 Patients with myositis frequently have autoantibodies associated with distinct clinical phenotypes. 2 Autoantibodies found exclusively in patients with myositis are known as myositis-specific autoantibodies (MSAs), whereas those that are also found in other autoimmune conditions are known as myositis-associated autoantibodies (MAAs). Interestingly, while the same autoantibodies found in adult myositis are also common in juvenile myositis, they are not always seen in the same frequency or associated with the same clinical features in both age groups. For example, autoantibodies against p155/140 (transcriptional intermediary factor1 (TIF-1)) are highly associated with malignancy in adults, but not in children. 3 Autoantibodies recognising cytosolic 5′-nucleotidase 1A (NT5C1A) were initially described in adults with IBM. 4 5 In these and subsequent studies, the reported prevalence of anti-NT5C1A autoantibodies in patients with IBM has ranged from 33% to 80%, depending on the patient population, type of assay used and the cut-offs chosen to define a positive result. [4] [5] [6] [7] [8] [9] [10] [11] [12] Importantly, since all studies have shown that <10% of adults with PM are positive for anti-NT5C1A, detection of this autoantibody may be a potentially useful biomarker for distinguishing these two forms of myositis. Subsequent studies demonstrated that anti-NT5C1A autoantibodies are also found in about 10%-15% of adult patients with DM and in 4%-36% of adult patients with lupus or Sjogren syndrome. 8 9 12 Given that they are found in myositis as well as in other autoimmune diseases, anti-NT5C1A can be defined as an adult MAA.
In adults with DM, no distinguishing clinical features have been identified for patients with anti-NT5C1A autoantibodies. 8 9 However, one study has shown that patients with anti-NT5C1A autoantibody-positive IBM are more likely to have dysphagia, facial weakness, reduced forced vital capacity and require assistive devices than those without these autoantibodies. 7 Consistent with the possibility that anti-NT5C1A autoantibodies confer a more severe disease phenotype, another recent paper showed that patients with IBM with this serological feature had a higher adjusted mortality risk than patients with autoantibody-negative IBM. 13 As anti-NT5C1A autoantibodies have not been previously described in children with myositis, the purpose of the present study was to define the prevalence and clinical features of anti-NT5C1A autoantibodies in a large cohort of patients with juvenile myositis. We also examined whether anti-NT5C1A autoantibodies are present in another paediatric rheumatological condition, juvenile idiopathic arthritis (JIA), towards determining if they are myositis-specific or myositis-associated autoantibodies in children.
PAtIents And MetHOds Patients and serum samples
Patients from the Childhood Myositis Heterogeneity Collaborative Study with probable or definite myositis by Bohan and Peter criteria 14 with a serum sample available for anti-NT5C1A autoantibody testing were included in the study. Serum samples, stored at −80°C from 1 to 27 years, were available from 380 children with myositis, 30 with JIA and 92 healthy control children. Patients with myositis included 307 (81%) with juvenile DM (JDM), 27 (7%) with juvenile PM (JPM) and 46 (12%) with juvenile connective tissue disease-myositis overlap (JCTM) syndromes. The JCTM subgroup included 7 patients with JIA, 14 with juvenile systemic lupus, 11 with systemic sclerosis and 14 with various other rheumatic conditions. Healthy control children were enrolled in the same studies and were often age-matched, gender-matched and race-matched to patients with myositis. They had no family history of autoimmune disease in first-degree relatives, no history of infections or immunisations within the 2 months prior to enrolment, and no history of chronic inflammatory diseases.
All subjects were enrolled in investigational review board-approved natural history studies from 1990 to 2016, as previously described, 15 and all provided informed consent. A standardised physician questionnaire captured demographics, clinical features, laboratory features, environmental exposures at illness onset or diagnosis, as well as therapeutic usage and responses. 15 Seven organ system symptom scores at diagnosis, defined as the number of symptoms present divided by the number of symptoms assessed, and an overall clinical symptom score as the average of the seven individual organ symptom scores were calculated as previously described. 16 17 Complete clinical response and remission were defined as at least 6 months of inactive disease on or off therapy, respectively. 17 A course of treatment was defined as a single episode from beginning of administration of a given medication to the termination of treatment with that medication, or combination of medications, in each patient. The majority of patients had verification of the data via medical record review. Human leucocyte antigen (HLA) typing of DRB1 and DQA1 alleles was performed as previously described. 18 Sera from a control group of healthy children was obtained in the same protocols, and sera from 39 patients with JIA were obtained from the NIEHS Twin Sibling study.
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Myositis autoantibody assays
Anti-NT5C1A autoantibody detection
As previously described, lysates of human embryonic kidney (HEK) 293 cells transfected with NT5C1A and non-transfected HEK 293 cell lysates were electrophoresed on sodium dodecyl sulfate-polyacrylamide gels, transferred to nitrocellulose membranes and immunoblotted with either a positive control rabbit polyclonal antibody recognising NT5C1A (Applied Biological Materials) or human sera diluted 1:1000 for 1 hour. To achieve uniformity between assays, each assay run included a positive control (ie, rabbit anti-NT5C1A immunoblotting non-transfected vs NT5C1A-transfected HEK 293 lysates). 8 Exposures of immunoblots in which the positive control lanes were of equivalent intensity were used for scoring. Human sera that recognised the 43-kd NT5C1A protein in NT5C1A transfected cells but not in untransfected cells were considered to be positive for anti-NT5C1A autoantibodies. All blots were independently scored by two readers (RY and ALM, who were blinded to sample identity) as being positive or negative for anti-NT5C1A reactivity. The inter-rater reproducibility for the positivity of this study was excellent, with an agreement of 96.1% and a Cohen's kappa coefficient of 0.90. In the few cases where there was disagreement, a third blinded reader (IPF) adjudicated.
Other myositis autoantibodies were tested by validated methods, including protein and RNA immunoprecipitation (IP) using radiolabelled HeLa or K562 cell extracts and double immunodiffusion. 15 For anti-p155/140, anti-MJ (Nuclear Matrix Protein 2, NXP2) and anti-melanoma differentiation-associated gene 5 (MDA5) autoantibodies, serum samples were screened by IP, with confirmation testing by IP immunoblotting. 15 Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) autoantibodies were screened by ELISA and confirmed by immunoprecipitation using a 35 S-methionine-labelled HMGCR protein produced by in vitro transcription and translation as previously described.
20
Analysis
Dichotomous variables were expressed as percentages and absolute frequencies, and continuous features were reported as means and SD. Pairwise comparisons for categorical variables between groups were made using χ 2 test or Fisher's exact test, as appropriate, while continuous variables were compared using Student t-test. Logistic and linear regression were used to adjust the comparisons for possible confounding variables, including the year of diagnosis, length of follow-up and myositis autoantibodies. Creatine kinase, a highly positively skewed variable, was expressed as median, first and third quartile for descriptive purposes and transformed through a base-10 logarithm for analysis. All statistical analyses were performed using Stata/MP V.14.1. As this was an exploratory study, a two-sided P value of ≤0.05 was considered statistically significant except for the HLA analyses, in which the Benjamini and Hochberg method to correct for multiple comparisons was performed.
results
Anti-NT5C1A autoantibodies were more prevalent in patients with juvenile myositis than in healthy control children (27% vs 12%; P=0.002) (table 1). Sera from 27% of patients with JDM, 11% with JPM and 35% with JCTM had anti-NT5C1A 
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autoantibodies. Among these clinical subgroups, the prevalence of anti-NT5C1A autoantibodies was significantly increased in patients with JDM (P=0.003) and JCTM (P=0.001), including those with lupus-myositis overlap (P=0.02), compared with healthy controls. Patients with JCTM had a higher prevalence of anti-NT5C1A autoantibodies than those with JPM (P=0.03); otherwise there were no significant differences in autoantibody prevalences among the JDM, JPM and JCTM subgroups. Of note, the prevalence of anti-NT5C1A autoantibodies was significantly increased in the children with JIA compared with healthy controls (27% vs 12%; P=0.02) (table 1) . There were no significant differences in gender or race between patients with juvenile myositis with and without anti-NT5C1A autoantibodies (table 2) . There was an association between the presence of anti-NT5C1A and anti-p155/140 autoantibodies, and fewer of the patients positive for anti-NT5C1A autoantibodies were negative for other MSAs. Specifically, 34% of the patients positive for anti-p155/140 autoantibodies were also positive for anti-NT5C1A autoantibodies compared with just 24% of patients negative for anti-p155/140 (P=0.04). Conversely, patients with anti-NT5C1A autoantibodies more frequently had coexisting anti-p155/140 autoantibodies than those who were negative for anti-NT5C1A autoantibodies (42% vs 31%, P=0.04). Of note, patients positive for anti-NT5C1A autoantibodies were more likely to have shorter follow-up times (4.4 vs 6.2 years, P=0.01) compared with patients negative for anti-NT5C1A autoantibodies (table 2) . Given these differences, subsequent multivariate analyses were adjusted for follow-up duration and the presence of myositis autoantibodies (including anti-p155/140 autoantibodies) as well as the year of diagnosis (considering that treatment strategies may have changed over time).
In the multivariate analysis comparing their clinical features, patients positive for anti-NT5C1A autoantibodies were more likely to have Raynaud's phenomenon and V-sign or shawl rashes compared with patients negative for anti-NT5C1A autoantibodies (table 3) . The prevalences of dysphonia and photosensitivity were increased among patients positive for anti-NT5C1A autoantibodies in the univariate analysis but not in the multivariate analysis, and there was a trend towards more frequent interstitial lung disease in those with anti-NT5C1A autoantibodies (table 3) . There were no other significant differences in the prevalences of the main muscle, lung, gastrointestinal, constitutional involvement or other cutaneous manifestations between these two groups in either univariate or multivariate analysis (table 3) .
A number of differences between patients positive and negative for the anti-NT5C1A autoantibodies suggested that patients with these autoantibodies had more severe disease. In the multivariate analysis, patients positive for anti-NT5C1A autoantibodies had higher pulmonary symptom scores (P=0.003) and showed a trend towards higher total symptom score (P=0.09) at the time of diagnosis (table 3). Patients positive for anti-NT5C1A autoantibodies had a higher mean number of hospitalisations (1.6 vs 1.1, P=0.01) than those without thieseautoantibodies. Furthermore, patients positive for the anti-NT5C1A autoantibodies required a greater number of medication treatments per year (4.8 vs 3.6, P≤0.001) with a higher percentage of patients requiring intravenous pulse steroids (78% vs 47%, P<0.001), intravenous immunoglobulin (67% vs 24%, P<0.001) and use of other immunosuppressive medications (33% vs 20%, P=0.04) (table 4). Patients positive for anti-NT5C1A autoantibodies had a trend for a more severe functional class at last assessment, but this did not reach statistical significance in the multivariate analysis (29% vs 18% functional class 2, P=0.08).
The multivariate analyses were adjusted for the presence or absence of each MSA. Consequently, our finding that anti-NT5C1A autoantibodies are associated with more severe disease is independent of the MSA status of the patient. Furthermore, when analysed separately, all patients negative for MSA, positive for anti-p155/140 autoantibodies and positive for anti-NXP2 autoantibodies had evidence of more severe disease when they were also positive for anti-NT5C1A autoantibodies (data not shown).
To determine whether there is an immunogenetic association with anti-NT5C1A autoantibodies, we compared the prevalence of HLA DRB1 and DQA1 alleles between Caucasian patients with juvenile myositis with and without this autoantibody. We also compared Caucasian patients with anti-NT5C1A autoantibodies with healthy Caucasian subjects and all patients positive for anti-NT5C1A with those negative for anti-NT5C1A autoantibodies. However, after multiple correction adjustment, no statistically significant associations between anti-NT5C1A autoantibodies and these class II MHC alleles were found in any of these comparisons.
dIsCussIOn
In adults, autoantibodies recognising NT5C1A are considered to be MAAs rather than MSAs because they are found not only in patients with myositis, but also in those with lupus and Sjogren syndrome. 8 9 In this study, we show that anti-NT5C1A autoantibodies are also MAAs in children since they are found not only in patients with juvenile myositis, but also in those with JIA. As expected for a MAA, we found that anti-NT5C1A autoantibodies were frequently found in association with other MSA, especially with anti-p155/140 autoantibodies. The prevalence of anti-NT5C1A autoantibodies varies among adults with different myositis subtypes. They occur most frequently in those with IBM, less frequently in DM and least frequently in those with PM. Here, we demonstrate that the prevalence of these autoantibodies in children also varies among myositis subtypes, with 27% of JDM but only 11% of patients with JPM testing positive for anti-NT5C1A autoantibodies. In the current study, we also found that anti-NT5C1A autoantibodies are present in 35% of children with myositis-overlap syndromes. Although the number of patients in each myositis overlap subgroup was small, the autoantibodies were found most commonly in those with myositis associated with juvenile lupus (36%), less frequently in myositis associated with juvenile systemic sclerosis (27%) and least frequently in those with myositis associated with JIA (14%). In adults, the prevalence of anti-NT5C1A autoantibodies was <5% in adults with myositisscleroderma overlap, 9 but future studies will be required to define the prevalence of anti-NT5C1A autoantibodies in adults with other forms of myositis-overlap.
In adults with IBM, anti-NT5C1A autoantibodies have been associated with more severe muscle disease 7 and increased mortality. 13 However, no evidence for an association between anti-NT5C1A autoantibodies and more severe disease in adults with other forms of myositis has been reported. Here, we demonstrate that in patients with juvenile myositis, these autoantibodies are associated with more frequent hospitalisations, higher pulmonary symptoms and increased number of medications used. The underlying reasons for the association of 
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anti-NT5C1A autoantibodies with more severe disease remain unclear, but may relate to a direct effect of the autoantibodies on myofibre protein degradation, as demonstrated in a study of passive transfer of anti-NT5C1A autoantibodies into mice. 21 Another possibility is that a more severe inflammatory response in juvenile myositis predisposes patients to the development of additional immunoreactivities such as that against NT5C1A. In some instances, individual autoantibodies have significant associations with specific HLA alleles. However, in this study, we did not find an association between the presence of anti-NT5C1A autoantibodies and any class II HLA alleles. This is consistent with a recent report by Limaye, showing no HLA associations in adult patients with IBM with anti-NT5C1A autoantibodies.
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In the current study, we were surprised to find that 11 out of 94 (12%) healthy children were positive for anti-NT5C1A autoantibodies detected by a previously validated immunoblotting assay. 7 We have demonstrated that 61% of adult patients with IBM and only 5% of adult patients with PM were anti-NT5C1A autoantibody-positive using the immunoblotting method, findings which are in agreement with an established dot blot technique 4 and an established immunoprecipitation technique. 5 In our previous study, we also found that 5% of healthy adult controls were anti-NT5C1A-positive by immunoblotting. 7 While another study reported that none of 32 adult healthy controls were anti-NT5C1A-positive by immunoprecipitation, 5 the prevalence of anti-NT5C1A autoantibodies in healthy adult controls has not been reported for the dot blot assay 4 or either of two different ELISA. 6 Nonetheless, taken together, these comparisons indicate that the anti-NT5C1A immunoblot assay performs as well as other detection methods and does not have an unacceptably high false positive rate. Of note, autoantibodies against Ro52, another common target of the immune system in various systemic autoimmune diseases, are also found in healthy controls as well as in patients with more severe disease manifestations. 22 When comparing the prevalence of anti-NT5C1A autoantibodies in children and adults within the same clinical groups using the same immunoblotting detection method, younger subjects consistently are more likely to have reactivity to these autoantibodies. For example, 27% of JDM but only 15% of adult patients with DM 7 are anti-NT5C1A autoantibody-positive (P=0.03). Similarly, 11% of JPM but only 5% of adult patients with PM 7 have these autoantibodies. Given that the same pattern is also observed among healthy children and healthy adults, we hypothesise that in both diseased and healthy groups, immunoreactivity against NT5C1A may decrease with age.
The current study has several limitations. First, the cohort of patients with juvenile myositis had some data collected retrospectively, resulting in some missing data, and was collected over >20 years, with potential chronology bias. However, we adjusted the variables of this study for the year of diagnosis and tested the distribution of missing values across groups and did not find evidence of a significant bias (data not shown). Second, we only screened a small number of patients with one other systemic autoimmune disease, JIA; the small sample size in this group of patients did not allow us to study differences in severity between patients with and without anti-NT5C1A autoantibodies in a reliable way. Future studies will be needed to determine the full range of paediatric rheumatological conditions in which anti-NT5C1A autoantibodies are found and to determine whether their presence correlates with disease severity or other clinical features. Third, there is no widely accepted 'gold standard' for detecting anti-NT5C1A autoantibodies. However, we have developed and validated an immunoblotting detection method. This technique has a sensitivity (61%) and specificity (95%) for detecting anti-NT5C1A autoantibodies in adult patients with IBM that is consistent with most other methods that utilise a full-length NT5C1A protein (sensitivity range 47%-80% and specificity range 95%-100%). [4] [5] [6] [7] [8] [9] [10] [11] [12] Of note, one published study utilising an ELISA method detected anti-NT5C1A autoantibodies in only 37% of patients with IBM. However, this assay used three short peptides rather than the full-length NT5C1A protein and the authors of the study acknowledged that it may have poor sensitivity since it cannot detect reactivity to conformational epitopes. 9 These limitations notwithstanding, this study shows that anti-NT5C1A autoantibodies are present in approximately one-quarter of patients with juvenile myositis as well as JIA. Furthermore, as shown for adults with IBM, patients with juvenile myositis with anti-NT5C1A autoantibodies have more severe disease than those without these autoantibodies. Additional studies will be required to confirm the association with disease severity in JM and to determine whether anti-NT5C1A autoantibodies are a result or a cause of the more severe clinical manifestations seen in the patients with juvenile myositis and adult patients with IBM who have them.
